Bit Capital Gmb H Incyte Corp Transaction History

Bit Capital Gmb H

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$65.08 - $83.38 $1.32 Million - $1.69 Million	-20,232 Closed	0 $0
Q3 2024 Feb 12, 2025	SELL	$57.33 - $68.61 $534,258 - $639,376	-9,319 Reduced 31.54%	20,232 $1.34 Billion
Q2 2024 Feb 12, 2025	BUY	$51.18 - $63.75 $363,224 - $452,433	7,097 Added 31.61%	29,551 $1.79 Billion
Q1 2024 Feb 12, 2025	BUY	$56.55 - $66.59 $1.17 Million - $1.38 Million	20,654 Added 1147.44%	22,454 $1.28 Billion
Q4 2023 Feb 12, 2025	BUY	$52.16 - $64.19 $93,888 - $115,542	1,800 New	1,800 $113 Million

676

186M

685K

533K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $14.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

Stay updated on Bit Capital Gmb H with notifications on news.